November 30, 2012 — iCAD Inc. launched VersaVue Enterprise 3.2.1, the latest release of the company’s MR software solution that provides improvements in workflow efficiency and flexibility, at the annual conference of the Radiological Society of North America (RSNA).
“The new VersaVue Enterprise solution will improve workflow and flexibility to aid clinical decision making and treatment for patients, with an ultimate goal of delivering improved patient care,” said Ken Ferry, President and CEO of iCAD.
VersaVue provides robust Dynamic Contrast Enhanced (DCE) MRI (magnetic resonance imaging) analysis and flexible review and reporting tools that facilitate standardization of kinetic analysis and interpretation and reporting of morphology. Using advanced thin client architecture, VersaVue delivers real-time data access and eliminates the need to purchase redundant hardware. The software features on-demand viewing of studies anytime, anywhere to speed workflow as well as shared knowledge of study status from a single, shared database. Unique features of VersaVue Enterprise 3.2.1 include:
- Fusion of ADC color overlays on any sequence
- On the fly 3 time point calculation (Quick TP)
- Fully automatic prostate segmentation of the capsule that will allow prostate volume reporting
VersaVue Enterprise is part of iCAD’s complete MRI product suite, which includes SpectraLook, VividLook and OmniLook. These products offer comprehensive quantitative image analysis for cancer detection, staging, localization, treatment planning and serial monitoring.
iCAD also be highlighted two prostate biopsy solutions at RSNA:
MRI Guided Prostate Biopsy (Currently pending FDA 510k clearance)
This solution will be a second generation system that will take advantage of the MR scanners gradient fields along with an innovative biopsy needle positioning device that is designed to provide radiologists with easier patient set-up, reduce the number of scans to identify and calculate target coordinates and reduce the total patient time in the magnet. The MRI guided solution is a works in progress project.
MR TRUS Fusion for Prostate Biopsy
The current TRUS procedure has limitations in target hit rate and accuracy. This next generation solution will improve target hit rate and accuracy, color coding significant tracks by Gleason scores and storing those tracks to compare for repeat biopsies particularly important for patients under active surveillance. The system uses a unique organ based tracking technology using 3D end-fire ultrasound probe and elastic Fusion technology to fuse MR with US images. MR TRUS Fusion is a solution that has product compatibility with the VersaVue Enterprise MR solution. With VersaVue Enterprise 3.2.1 release there will be expanded features that will be compatible with the MR TRUS Fusion solution.
Additionally, iCAD’s workstation was used to process the MR images used in a neuroradiology study that examined brain meningiomas. A scientific paper presenting the study’s findings titled, “Intracranial Tumor Extravascular Extracellular Space: Examining the Correlation Between ADC and DCE MRI Metrics in Human Meningioma,” were presented at RSNA.
iCAD also showcased its next generation computer-aided detection (CAD) system for digital mammography, the PowerLook Advanced Mammography Platform (AMP). The modular design of PowerLook AMP provides radiologists with the ability to customize their CAD solution to meet the needs of their individual work environment today and in the future. The technology expands on iCAD’s SecondLook Digital solution and is the CAD platform upon which all future breast imaging CAD offerings from iCAD will be built. PowerLook AMP’s CAD metrics offer industry-leading tissue and lesion characteristics to support the breast imager’s workflow. In addition, PowerLook AMP is the first product of its kind to integrate M?takina’s Volpara Volumetric Breast Density assessment software that aids radiologists by standardizing their approach to breast density assessment.
For more information: www.icadmed.com
April 23, 2024 
